| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director, 10% Owner
1 company
John M Desmarais last filed a Form 4 in March 2019, as Director, 10% Owner at BRTX. John M Desmarais's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 493,398 shares of BRTX. Net of sales, the BRTX filings show accumulation of 330,000 shares.
John M Desmarais has 13 Form 4 filings on record from December 2015 to March 2019, all as Director, 10% Owner at BioRestorative Therapies (BRTX), 2015–2019.
The 43 reported transactions were 16 option or other derivative awards, 11 open-market purchases, 10 dispositions back to the company and 4 open-market sales, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 2 purchases worth about $1.2M and no sales.
The largest open-market purchase was 250,000 shares of BRTX at an average $4.00 on March 18, 2016, about $1.0M.
Shares as reported in the last Form 4 for each company; the most recent is from March 2019. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.